NL-OMON56928尚未招募不适用
Selecting Ovarian Cancer patients for PARP Inhibitor (SOPI) study - SOPI study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 778
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •For biopsy:
- •- Women with suspected EOC, aged 18 years or older who give informed consent
- •for routine diagnostics including the sample for the HRD tests. In a
- •subpopulation we will compare HRD tests on tissue obtained at interval CRS as
- •- Written informed consent
- •For Follow-up PARP-i:
- •- Patients with FIGO Stage III and IV EOC cancer who received standard of care
- •with debulking surgery and platinum based chemotherapy and are eligible for
- •PARP-i according to at least one positive HRD test.
- •- Patients with germline or somatic BRCA1/2 pathogenic variants in the tumor
- •will be asked to participate as (positive) controls
- •- Patients without BRCA1/2 pathogenic variant or HRD: only registration of PFS,
- •QOL and OS.
- •Control group:
- •- Included in the PlaComOv study (MEC-2017-500/NL62035.078.17) and given
- •informed consent for the use of data for future research.
排除标准
- •- Impossibility to obtain HRD test
- •- Other diagnosis than epithelial ovarian cancer
- •- Mucinous, low grade serous or clear cell type ovarian cancer
- •- Ineligibility for PARP-i treatment: such as (but not exclusive)
- •o Not reached at least partial response to neoadjuvant chemotherapy
- •o FIGO stage I-II disease
- •o All HRD tests negative and no BRCA 1/2 carrier
- •- Patients who are not able to understand/sign the Informed Consent.
- •- Known germline BRAC1/2 mutation
研究者
相似试验
招募中
2 期
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiOvarian CancerNCT05551208Chongqing University Cancer Hospital42
已完成
不适用
Targeted screening for ovarian cancer in women over 50 years of age with vague presenting symptomsOvarian cancerMalignant neoplasm of ovaryCancerISRCTN04011070Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
招募中
不适用
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR InhibitorsOvarian CancerNCT05640024Yonsei University54
Unknown
2 期
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerOvarian and Fallopian Tube Cysts and NeoplasmsOvarian CancerNeoplasms by SiteNeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, Ovarian EpithelialOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleCarcinomaAnlotinibPARP InhibitorsBRCA1 MutationAngiogenesisAntineoplastic AgentsBRCA2 MutationNCT04566952Xiaoxiang Chen68
招募中
不适用
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Ovarian CancerNCT05458973Yonsei University100